新型气动驱动ECMO装置的安全性与有效性动物实验
该研究在6只健康清醒绵羊中评估新型全气动驱动ECMO装置(Mobybox)以静脉-静脉模式运行7天的安全性和有效性。结果显示该装置在低扫气流量下可有效清除二氧化碳并维持氧合,无可见凝血、溶血或持续性血小板及纤维蛋白原降低。
要点
- 气动驱动ECMO装置在7天绵羊实验中未出现可见凝血或溶血。
- 低扫气流量0.3 L/min下PCO2从膜前38–44 mmHg降至膜后32–36 mmHg。
- 血小板第2天从177±53/μL降至107±28/μL,第7天恢复至180±51/μL。
核心结论
- 气动驱动ECMO装置在7天绵羊实验中提供了良好的安全性和生理有效性,无可见凝血、溶血或持续性纤维蛋白原及血小板降低。
研究设计与样本
- 动物实验:6只健康清醒绵羊接受Mobybox ECMO装置以静脉-静脉模式治疗7天,评估气体交换、凝血参数和安全性。
主要发现
- 血流量2 L/min、低扫气流量0.3 L/min时,膜前PCO2为38–44 mmHg,膜后降至32–36 mmHg。
- 膜后PaO2增至600 mmHg。
- 较高扫气流量导致部分动物自主呼吸停止,故维持低扫气流量。
- 血小板第2天从177±53/μL降至107±28/μL,第7天恢复至180±51/μL。
- 血浆游离血红蛋白保持低水平(2–9 mg/dL),纤维蛋白原轻微升高后保持稳定,7天后泵和氧合器无可见凝血。
临床怎么用
- 该装置在动物模型中显示可安全用于静脉-静脉ECMO支持,但临床转化前仍需进一步验证。
局限性
- 样本量小(6只绵羊),仅评估静脉-静脉模式,未涉及静脉-动脉模式或临床患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Extracorporeal membrane oxygenation (ECMO) is rapidly becoming a mainstream technology for lung or heart/lung support. Current ECMO devices mostly consist of a power-driven centrifugal pump and a dedicated oxygenator. We studied the safety and efficacy of a novel, fully pneumatically driven ECMO device, which could be used in both venovenous or venoarterial mode in an animal model. METHODS: Six healthy, awake sheep were treated with the Mobybox ECMO device (Hemovent, Aachen, Germany) over a 7-day period in a venovenous mode. Gas exchange, coagulation parameters, and safety were assessed. RESULTS: Using a blood flow rate of 2 L/min and a low sweep gas flow rate of 0.3 L/min, the PCO2 ranged from 38 to 44 mm Hg pre oxygenator and dropped to 32 to 36 mm Hg post oxygenator, whereas the PaO2 post oxygenator increased to 600 mm Hg. Higher levels of sweep gas flow resulted in cessation of spontaneous breathing in some animals, consistent with high-efficiency carbon dioxide removal; thus, the sweep gas flow rate was maintained at a low level. Platelets dropped from 177 ± 53/μL to 107 ± 28/μL on day 2, while returning to baseline by day 7 (180 ± 51/μL). Plasma-free hemoglobin remained low (2-9 mg/dL), whereas fibrinogen slightly increased, and then remained stable throughout the period. Neither the pump nor the oxygenator showed any visible clotting after 7 days. CONCLUSIONS: The pneumatically driven ECMO device provided excellent safety and physiologic efficacy in a 7-day sheep experiment without visible clotting, hemolysis, or sustained reductions in fibrinogen or platelets.
引用
- Karagiannidis C, Joost T, Strassmann S, et al. Safety and Efficacy of a Novel Pneumatically Driven Extracorporeal Membrane Oxygenation Device. Ann Thorac Surg. 2020. PMID: 32119858. doi:10.1016/j.athoracsur.2020.01.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。